Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions
- PMID: 12202207
- DOI: 10.1006/viro.2002.1520
Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions
Abstract
We have shown that a bacteriophage lambda genetic screen system may be useful in predicting the activity and phenotype of HIV-1 protease in the course of viral infection and antiretroviral therapy. This simple and rapid genetic screening system has been used here to characterize HIV-1 proteases encoding single primary resistance substitutions. Except for proteases with amino acid changes at positions 46 and 84, proteases containing single-resistance substitutions displayed a lower catalytic efficiency than the WT enzyme. Single mutants could be identified by their efficiency, demonstrating that modest differences in protease activity can be monitored with this simple assay. Overall, drug susceptibility could be reduced by introduction of single mutations. However, high-level protease inhibitor (PI) resistance was only achieved by multiple mutated proteases. The small but reproducible increase in resistance displayed by single mutants also demonstrated the ability of this genetic screen system for detecting minor reductions in drug susceptibility. These results show that the bacteriophage lambda genetic screen system used here is a useful tool in the analysis of specific contribution of mutations in the HIV protease-coding region or in specific cleavage sites that affect the process of PI resistance.
Similar articles
-
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.PLoS Med. 2007 Jan;4(1):e36. doi: 10.1371/journal.pmed.0040036. PLoS Med. 2007. PMID: 17227139 Free PMC article.
-
A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.Biochemistry. 2003 Jan 28;42(3):631-8. doi: 10.1021/bi027019u. Biochemistry. 2003. PMID: 12534275
-
Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.Antimicrob Agents Chemother. 2016 Mar 25;60(4):2248-56. doi: 10.1128/AAC.02682-15. Print 2016 Apr. Antimicrob Agents Chemother. 2016. PMID: 26833162 Free PMC article. Clinical Trial.
-
The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.Antivir Ther. 2004 Jun;9(3):301-14. Antivir Ther. 2004. PMID: 15259893 Review.
-
Polymorphisms in HIV-1 subtype C proteases and the potential impact on protease inhibitors.Trop Med Int Health. 2008 Feb;13(2):144-51. doi: 10.1111/j.1365-3156.2007.01984.x. Trop Med Int Health. 2008. PMID: 18304259 Review.
Cited by
-
Fitness landscape of human immunodeficiency virus type 1 protease quasispecies.J Virol. 2007 Mar;81(5):2485-96. doi: 10.1128/JVI.01594-06. Epub 2006 Dec 6. J Virol. 2007. PMID: 17151104 Free PMC article.
-
Genetic screen for monitoring hepatitis C virus NS3 serine protease activity.Antimicrob Agents Chemother. 2003 May;47(5):1760-5. doi: 10.1128/AAC.47.5.1760-1765.2003. Antimicrob Agents Chemother. 2003. PMID: 12709356 Free PMC article.
-
Genetic screen for monitoring severe acute respiratory syndrome coronavirus 3C-like protease.J Virol. 2004 Dec;78(24):14057-61. doi: 10.1128/JVI.78.24.14057-14061.2004. J Virol. 2004. PMID: 15564515 Free PMC article.
-
HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions.Mol Biol Evol. 2007 Feb;24(2):382-7. doi: 10.1093/molbev/msl168. Epub 2006 Nov 7. Mol Biol Evol. 2007. PMID: 17090696 Free PMC article.
-
Epistasis as a determinant of the HIV-1 protease's robustness to mutation.PLoS One. 2014 Dec 31;9(12):e116301. doi: 10.1371/journal.pone.0116301. eCollection 2014. PLoS One. 2014. PMID: 25551558 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous